Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun 1;9(7):FSO871.
doi: 10.2144/fsoa-2022-0081. eCollection 2023 Aug.

Ocular complications of antineoplastic therapies

Abbas Bader  1 , Madeline Begemann  2 , Ammar Al-Obaidi  2 , Muhammad Hamza Habib  3 , Faiz Anwer  4 , Shahzad Raza  4
Affiliations
Review

Ocular complications of antineoplastic therapies

Abbas Bader et al. Future Sci OA. .

Abstract

Ocular complications of antineoplastic agents can have a profound effect on the quality of life of cancer patients. New oncologic treatments like monoclonal antibodies, immunotherapies, antibody-drug conjugates, checkpoint inhibitors and growth factor receptors have resulted in increased ocular complications. These ocular complications differs in respect to distinct mechanisms of actions and lead to significant challenges in the management of cancer patients. In this review, we reviewed literature, clinical studies and cases detailing ocular complications due to administration of antineoplastic agents and emphasized the need for communication between oncologists and ophthalmologists toward early detection and management of ocular complications.

Keywords: antineoplastic agents; cancer; chemotherapy; ophthalmic side effects.

Plain language summary

Ocular side effects can have a large impact on the quality of life on patients with cancer. New ways to treat cancer greatly increased patient prognosis, however, it has also resulted in increased ocular complications. This paper aims to review past medical literature, clinical studies, and case reports to describe the types of ocular complications that may arise from administration of antineoplastic agents. This paper emphasizes the need for communication between oncologists and ophthalmologists toward early detection and management for better patient care.

PubMed Disclaimer

Conflict of interest statement

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

References

    1. Kondo N, Takahashi A, Ono K, Ohnishi T. DNA damage induced by alkylating agents and repair pathways. J. Nucleic Acids. 2010, 543531 (2010). - PMC - PubMed
    1. Brown A, Kumar S, Tchounwou PB. Cisplatin-Based Chemotherapy of Human Cancers. J. Cancer Sci. Ther. 11(4), 97 (2019). - PMC - PubMed
    1. Li Y, Li Y, Li J, Pi G, Tan W. Paclitaxel- and/or cisplatin-induced ocular neurotoxicity: a case report and literature review. Onco. Targets Ther. 7, 1361–1366 (2014). - PMC - PubMed
    1. Wilding G, Caruso R, Lawrence TS et al. Retinal toxicity after high-dose cisplatin therapy. J. Clin. Oncol. 3(12), 1683–1689 (1985). - PubMed
    1. Caraceni A, Martini C, Spatti G, Thomas A, Onofrj M. Recovering optic neuritis during systemic cisplatin and carboplatin chemotherapy. Acta. Neurol. Scand. 96(4), 260–261 (1997). - PubMed

LinkOut - more resources